205 related articles for article (PubMed ID: 31260484)
1. Loss of function Cbl-c mutations in solid tumors.
Daniels SR; Liyasova M; Kales SC; Nau MM; Ryan PE; Green JE; Lipkowitz S
PLoS One; 2019; 14(7):e0219143. PubMed ID: 31260484
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
[TBL] [Abstract][Full Text] [Related]
3. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
[TBL] [Abstract][Full Text] [Related]
4. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.
Nadeau SA; An W; Mohapatra BC; Mushtaq I; Bielecki TA; Luan H; Zutshi N; Ahmad G; Storck MD; Sanada M; Ogawa S; Band V; Band H
J Biol Chem; 2017 Mar; 292(9):3666-3682. PubMed ID: 28082680
[TBL] [Abstract][Full Text] [Related]
5. EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.
Davies GC; Ryan PE; Rahman L; Zajac-Kaye M; Lipkowitz S
Oncogene; 2006 Oct; 25(49):6497-509. PubMed ID: 16702950
[TBL] [Abstract][Full Text] [Related]
6. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
7. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
9. The Cbl RING finger C-terminal flank controls epidermal growth factor receptor fate downstream of receptor ubiquitination.
Visser GD; Lill NL
Exp Cell Res; 2005 Dec; 311(2):281-93. PubMed ID: 16246327
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line.
Bisson SA; Ujack EE; Robbins SM
Oncogene; 2002 May; 21(23):3677-87. PubMed ID: 12032836
[TBL] [Abstract][Full Text] [Related]
11. Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases.
Kowanetz K; Crosetto N; Haglund K; Schmidt MHH; Heldin CH; Dikic I
J Biol Chem; 2004 Jul; 279(31):32786-95. PubMed ID: 15159412
[TBL] [Abstract][Full Text] [Related]
12. Cbl interacts with multiple E2s in vitro and in cells.
Liyasova MS; Ma K; Voeller D; Ryan PE; Chen J; Klevit RE; Lipkowitz S
PLoS One; 2019; 14(5):e0216967. PubMed ID: 31120930
[TBL] [Abstract][Full Text] [Related]
13. CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.
Calco GN; Stephens OR; Donahue LM; Tsui CC; Pierchala BA
J Biol Chem; 2014 Mar; 289(11):7307-19. PubMed ID: 24425877
[TBL] [Abstract][Full Text] [Related]
14. Lack of RING finger domain (RFD) mutations of the c-cbl gene in oral squamous cell carcinomas in Chennai, India.
Rajendran S; Muthupalani RS; Ramanathan A
Asian Pac J Cancer Prev; 2013; 14(2):1073-5. PubMed ID: 23621189
[TBL] [Abstract][Full Text] [Related]
15. Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
Kales SC; Nau MM; Merchant AS; Lipkowitz S
PLoS One; 2014; 9(1):e87116. PubMed ID: 24466333
[TBL] [Abstract][Full Text] [Related]
16. Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Sargin B; Choudhary C; Crosetto N; Schmidt MHH; Grundler R; Rensinghoff M; Thiessen C; Tickenbrock L; Schwäble J; Brandts C; August B; Koschmieder S; Bandi SR; Duyster J; Berdel WE; Müller-Tidow C; Dikic I; Serve H
Blood; 2007 Aug; 110(3):1004-12. PubMed ID: 17446348
[TBL] [Abstract][Full Text] [Related]
17. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
Rathinam C; Thien CB; Flavell RA; Langdon WY
Cancer Cell; 2010 Oct; 18(4):341-52. PubMed ID: 20951944
[TBL] [Abstract][Full Text] [Related]
18. Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion.
Thien CB; Blystad FD; Zhan Y; Lew AM; Voigt V; Andoniou CE; Langdon WY
EMBO J; 2005 Nov; 24(21):3807-19. PubMed ID: 16211006
[TBL] [Abstract][Full Text] [Related]
19. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
20. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor.
Zuo W; Huang F; Chiang YJ; Li M; Du J; Ding Y; Zhang T; Lee HW; Jeong LS; Chen Y; Deng H; Feng XH; Luo S; Gao C; Chen YG
Mol Cell; 2013 Feb; 49(3):499-510. PubMed ID: 23290524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
